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ABSTRACT 22 
Porcine reproductive and respiratory syndrome virus (PRRSV) is the causative agent of 23 
arguably the most economically important global swine disease. The extensive genetic 24 
variation of PRRSV strains is a major obstacle for heterologous protection of current 25 
vaccines. Previously, we constructed a panel of chimeric viruses containing only the 26 
ectodomain sequences of DNA-shuffled structural genes of different PRRSV strains in the 27 
backbone of a commercial vaccine, and found that one chimeric virus had an improved 28 
cross-protection efficacy. In this present study, to further enhance the cross-protective 29 
efficacy against heterologous strains, we constructed a novel chimeric virus VR2385-S3456 30 
containing the full-length sequences of shuffled structural genes (ORFs 3-6) from 6 31 
heterologous PRRSV strains in the backbone of PRRSV strain VR2385. We showed that the 32 
chimeric virus VR2385-S3456 induced a high level of neutralizing antibodies in pigs against 33 
two heterologous strains. A subsequent vaccination and challenge study in 48 pigs revealed 34 
that the chimeric virus VR2385-S3456 conferred an enhanced cross-protection when 35 
challenged with heterologous virus strain NADC20 or a contemporary heterologous strain 36 
RFLP 1-7-4. The results suggest that the chimera VR2385-S3456 may be a good PRRSV 37 
vaccine candidate for further development to confer heterologous protection. 38 
 39 
Key words: Porcine reproductive and respiratory syndrome virus (PRRSV); vaccine; DNA 40 
shuffling; cross-protection; heterologous strains; RFLP 1-7-4.  41 
 42 
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1. Introduction 44 
Porcine reproductive and respiratory syndrome virus (PRRSV) causes an economically 45 
important global swine disease resulting in more than $660 million annual economic losses to 46 
the swine industry in the United States alone [1, 2]. As a single-strand positive-sense RNA 47 
virus, PRRSV has an extremely high mutation rate which is approximately 10-2/site/year 48 
[3-6]. Field strains with extensive genetic variations have been frequently emerging since its 49 
initial isolation from pigs in 1989 [3, 7, 8]. These diverse populations of virus strains are 50 
classified into two distinct genotypes, type 1 and type 2, and at least 9 distinct genetic 51 
lineages can be subdivided within type 2 [7, 8]. The current commercially available vaccines 52 
only confer a limited level of cross-protection against heterologous PRRSV strains [9-11]. 53 
Therefore, an important objective for PRRSV control is to develop a universal vaccine that 54 
can provide better heterologous protection than the current available vaccines [12, 13]. 55 
One promising strategy to achieve this objective is to include protective immunogenic 56 
domains from different strains in the vaccine by molecular breeding of multiple heterologous 57 
strains through DNA shuffling. By mimicking natural recombination process in vivo, DNA 58 
shuffling can rapidly generate recombinants with desired phenotypes in vitro [14]. The DNA 59 
shuffling approach has been successfully used to generate desired phenotypes of viruses such 60 
as Murine leukemia virus strains, Dengue virus, and Venezuelan equine encephalitis virus 61 
[15-17]. 62 
The PRRSV genome encodes at least eight structural proteins, most of which are important 63 
for protective immunity [18, 19]. The major envelope glycoprotein GP5 has been extensively 64 
studied as a target for PRRSV vaccine development since it contains neutralizing epitopes 65 
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and contributes to virus entry into cells through heterodimers formed with membrane protein 66 
(M). GP5 has also been showed to be responsible for PRRSV virulence [20-24]. Minor 67 
envelope glycoproteins (GP2, GP3, GP4) also induce neutralizing antibodies and play 68 
important roles in cell entry by interacting with the cellular receptor CD163 [25-28]. 69 
Therefore, for the rational design of a broadly cross-protective vaccine, both major and minor 70 
PRRSV envelope proteins should be considered. 71 
Previously, we have individually shuffled each of the GP3, GP4, GP5, and M genes in the 72 
backbone of PRRSV virulent strain VR2385 through DNA shuffling [29-31]. We identified 73 
chimeric viruses with improved cross-neutralizing activities against heterologous virus strains 74 
in vitro. Furthermore, we demonstrated that, when the ectodomain sequences of these 75 
individually-shuffled structural genes were assembled into the backbone of a commercial 76 
vaccine (Fostera® PRRS), the resulting chimeria FV-SPDS-VR2 conferred improved 77 
heterologous protection [32]. 78 
In this present study, we hypothesized that inclusion of the full-length, not just the 79 
ectodomain, sequences of each individually-shuffled structural genes in the backbone of 80 
PRRSV strain VR2385, which is the original backbone used to screen for individual chimeras 81 
with improved cross-neutralizing activities, would further improve the heterologous 82 
protection. Therefore, a novel chimeric virus VR2385-S3456 containing the full-length 83 
sequences of all shuffled structural genes in the backbone of VR2385 strain was generated in 84 
this study, and shown to induce cross-protection in pigs challenged with heterologous strain 85 
NADC20 and a contemporary heterologous strain RFLP 1-7-4.  86 
 87 
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2. Materials and methods 88 
2.1. Cells and viruses  89 
BHK-21 cells were cultured in Dulbecco’s Minimal Essential Medium (DMEM) 90 
supplemented with 10% fetal bovine serum (FBS). Monkey kidney cell lines MARC-145 91 
were cultured in low glucose-supplemented DMEM with 10% FBS, and maintained in low 92 
glucose DMEM with 2% FBS for virus propagation. A DNA-launched infectious clone of 93 
PRRSV strain VR2385, pIR-VR2385-CA, was constructed previously [33]. PRRSV strain 94 
VR2385 (lineage 5, accession no. JX044140) was originally isolated from a pig experiencing 95 
severe respiratory disease in Iowa [34, 35]. The attenuated PRRSV strain DS722, a derivative 96 
of VR2385 generated by DNA shuffling of the ORF5 gene, was constructed in our lab 97 
previously [30]. The PRRSV strain NADC20 (lineage 9, accession no. JX069953) was 98 
provided by Dr. Kelly Lager of USDA-National Animal Disease Center [8]. A contemporary 99 
PRRSV strain ISU2014016404 (referred to as “RFLP 1-7-4”) belonging to lineage 1 with a 100 
pattern 1-7-4 based on restriction fragment length polymorphism (RFLP) pattern of the ORF5 101 
gene was provided by Dr. Jianqiang Zhang of the Iowa State University [36].  102 
2.2. Construction and rescue of chimeric virus  103 
A nucleotide acid sequence fragment S3456 was designed and commercially synthesized 104 
(Integrated DNA Technologies, Coralville, Iowa). The S3456 fragment contains the 105 
full-length sequences of the shuffled ORF3 gene derived from chimera GP3TS22 [29], 106 
shuffled ORF4 gene derived from chimera GP4TS14 [31], shuffled ORF5 gene derived from 107 
chimera DS722 [30], and shuffled ORF6 (M) gene derived from chimera MTS57 [31]. The 108 
overlapping sequences between ORF3 and ORF4 were derived from chimera GP4TS14. The 109 
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inclusion of the shuffled ORF5 gene from chimera DS722 ensured that the resulting virus is 110 
attenuated, as the DS722 chimera with the shuffled ORF5 gene is attenuated in pigs [30]. By 111 
using the BsrG I and Xba I restriction enzyme sites engineered into the synthesized fragment 112 
S3456, the full-length sequences of the shuffled ORFs 3-6 were successfully introduced into 113 
the genomic backbone of a DNA-launched PRRSV infectious clone pIR-VR2385-CA, to 114 
create the final chimera designated VR2385-S3456 (Fig. 1A).  115 
To rescue the chimeric virus VR2385-S3456, fresh BHK-21 cells seeded in a 6-well plate 116 
at approximately 60–80% confluency were transfected with 2 µg of the respective plasmid 117 
DNA per well using the Lipofectamine LTX and Plus Reagent kit (Invitrogen) according to 118 
the manufacturer’s instructions. After 48 h incubation at 37°C with 5% CO2, cell culture 119 
supernatants were harvested and designated as passage 0 (P0) virus.  120 
2.3. Indirect immunofluorescence assay (IFA)  121 
IFA with an anti-PRRSV antibody (SDOW17) was used to verify PRRSV infection in cells 122 
as described previously [28].  123 
2.4. Virus growth kinetics and plaque morphology assay 124 
To characterize the growth kinetics and properties of the rescued chimeric virus 125 
VR2385-S3456 in vitro, a multiple-step growth curve and plaque morphology assays were 126 
conducted in MARC-145 cells as described previously [28].  127 
2.5. Experimental design for a cross-protection vaccine efficacy study in pigs  128 
This study was approved by Virginia Tech Institutional Animal Care and Use Committee 129 
(approval number 16-127). A total of 48 PRRSV-negative piglets all at 3 weeks of age were 130 
randomly divided into 6 groups of 8 piglets per group regardless of the body weights. Piglets 131 
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in each group were vaccinated intramuscularly with the novel chimera VR2385-S3456, an 132 
attenuated chimera DS722 containing only shuffled ORF5 [30], or PBS (Table 1). Serum 133 
samples were collected from each pig prior to vaccination and weekly thereafter. At 49 days 134 
post-vaccination (dpv), the pigs were challenged with one of two heterologous PRRSV 135 
strains, NADC20 or RFLP 1-7-4 which share 92.9% and 88.2% nucleotide sequence identity 136 
in the ORF5 gene with the VR2385-S3456, respectively. At 14 days post-challenge (dpc), all 137 
pigs were euthanized and necropsied. Lung tissue samples were collected for gross pathology 138 
and histopathology evaluation and quantification of PRRSV RNA load.  139 
2.6. Serum virus neutralization (SVN) assay 140 
The neutralizing antibody (NA) titers against heterologous strains NADC20 and RFLP 141 
1-7-4 were determined by a SVN assay [29]. Briefly, two-fold diluted serum samples 142 
collected at 49 dpv from each pig were mixed with an equal volume of respective test virus at 143 
an infectious titer of 2×103 TCID50/ml and incubated at 37°C for 1 h. The mixture was then 144 
dispensed onto MARC-145 cells in 96-well plates (100 ml/well) and incubated for 1 h at 145 
37°C. After washing with PBS once, the cells were maintained in DMEM (2% FBS) for 20 h. 146 
The cells were fixed and stained for IFA to detect evidence of virus infection. The NA titers 147 
were expressed as the highest dilution that showed at least 90% reduction in the number of 148 
fluorescent foci compared to negative control serum. Three independent tests were performed 149 
for each serum sample. 150 
2.7. Gross pathology and histopathology evaluation of lung tissues 151 
At necropsy, lungs were evaluated for visible gross lesions as described previously [35], 152 
and subsequently five sections of lung tissues were collected, fixed in formalin and processed 153 
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for histopathology evaluation. The evaluation was conducted by a board-certified veterinary 154 
pathologist who was blinded to the treatment status. For the histopathology evaluation, the 155 
microscopic lung lesions were scored based on the presence and severity of interstitial 156 
pneumonia ranging from 0 to 4 (0, no microscopic lesions; 1, mild interstitial pneumonia; 2, 157 
moderate multifocal interstitial pneumonia; 3, moderate diffuse interstitial pneumonia; 4, 158 
severe interstitial pneumonia).  159 
2.8. Quantitation of viral RNA loads in sera and lung tissues 160 
 Serum viral RNAs were extracted from serum samples at 49 dpv, 7 and 14 dpc using ZR 161 
Viral RNA kit (ZYMO RESEARCH, USA) following the manufacturer’s protocol. Total 162 
RNAs from the lung tissue were extracted using TRI Reagent (MRC) following the 163 
manufacturer’s protocol. The quantitation of PRRSV RNA copy number was conducted by 164 
RT-qPCR as described previously [30, 32]. 165 
2.9. Statistical analyses 166 
The data were analyzed using GraphPad Prism (version 6.0).  The viral titers were 167 
analyzed by the Student’s t test (unpaired), and the other data were analyzed using one-way 168 
ANOVA followed by Tukey’s multiple comparison test.  169 
 170 
3. Results 171 
3.1. Successful rescue of chimeric virus VR2385-S3456 containing the full-length sequences 172 
of shuffled ORFs 3-6 genes of multiple heterologous strains 173 
Previously, we have successfully generated single envelope gene-shuffled chimeric 174 
PRRSV viruses (GP3TS22, GP4TS14, DS722 and MTS57), in the genomic backbone of a 175 
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virulent PRRSV strain VR2385, as well as a multiple genes-shuffled chimeric virus 176 
(FV-SPDS-VR2) in the backbone of commercial vaccine Fostera® PRRS [29-32]. In an 177 
attempt to further improve the efficacy of cross-protection, in this present study we included 178 
the full-length sequences, not just the ectodomain sequences, of all shuffled structural genes 179 
in the genomic backbone of PRRSV strain VR2385. The rationale is that additional 180 
cross-protective epitopes reside in regions other than the ectodomains. Also, the use of 181 
wild-type PRRSV VR2385 (instead of a MLV) would also enhance humoral and 182 
cell-mediated immune responses.  183 
The DNA fragment S3456 representing the full-length sequences of shuffled ORFs3-6 184 
derived from multiple chimeras with respective individually-shuffled gene was commercially 185 
synthesized (Fig. 1A). The S3456 was cloned into the backbone of a DNA-launched 186 
infectious clone pIR-VR2385-CA to produce a novel chimera VR2385-S3456. The 187 
authenticity of the chimeric clone VR2385-S3456 was verified by DNA sequencing.  188 
Following transfection of BHK-21 cells with the full-length chimeric clone VR2385-S3456, 189 
supernatant was harvested two days post-transfection (P0 virus) and used to inoculate fresh 190 
MARC-145 cells. At four days post-inoculation, cytopathic effects (CPEs) were observed in 191 
inoculated cells. IFA using PRRSV N-specific monoclonal antibody confirmed that the CPEs 192 
were PRRSV-specific, thus indicative of the production of viable progeny viruses (Fig. 1B). 193 
To further confirm that the rescued virus indeed originated from the clone, the ORFs3-6 194 
genes were amplified from the P3 viruses by RT-PCR and sequenced. Sequence data (not 195 
shown) confirmed that the ORFs3-6 of the rescued virus were identical to that of the original 196 
chimeric clone. Therefore, the results demonstrated the successful rescue of a viable novel 197 
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chimeric virus VR2385-S3456 containing the full-length sequences of the shuffled ORFs 3-6 198 
genes. 199 
3.2. Chimeric virus VR2385-S3456 had a reduced growth ability phenotype in MARC-145 200 
cells 201 
To evaluate the growth kinetics of the rescued VR2385-S3456, MARC-145 cells were 202 
infected with the P3 virus of the VR2385-S3456 or VR2385 at an MOI of 0.1. The chimeric 203 
virus VR2385-S3456 had an overall reduced growth ability when compared to VR2385 (Fig. 204 
1C). Specifically, compared to parental virus VR2385, the chimera VR2385-S3456 had 205 
significantly lower virus titers between 48 to 96 h post-inoculation (hpi). The peak virus titer 206 
of the parental virus VR2385 was approximately 3.0×107 TCID50/ml, whereas the peak titer 207 
of the chimera VR2385-S3456 was about 3.0×105 TCID50/ml, 100 times lower than the 208 
parental virus. Compared to the parental virus, the chimeric virus formed smaller and turbid 209 
plaques (Fig. 1D) in MARC-145 cells indicating a reduced rate of growth and spread to 210 
adjacent cells. This is consistent with the observations on growth kinetics. Collectively, the 211 
results showed that the chimeric virus VR2385-S3456 containing the full-length sequences of 212 
the shuffled ORFs3-6 genes are viable and have a reduced growth ability in MARC-145 cells. 213 
3.3. Chimeric virus VR2385-S3456 induced higher cross-neutralizing antibodies against 214 
heterologous virus strains NADC20 and RFLP 1-7-4 215 
To evaluate the efficacy of heterologous protection of the chimeric virus VR2385-S3456, 216 
we conducted a vaccination/challenge study in pigs. Since the PRRSV strain VR2385 is a 217 
virulent strain [35], a derivative of VR2385, chimera DS722, which contains a shuffled GP5 218 
gene and is attenuated, was used as the control [30]. After vaccination, the anti-PRRSV 219 
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antibodies in each pig were monitored using the IDEXX HerdChek X3 ELISA kit. The data 220 
showed that all vaccinated pigs seroconverted at 14 dpv, while the negative control group 221 
pigs remained seronegative until after challenge (Table 2).  222 
To investigate whether the chimeric virus induces cross-neutralizing antibodies against 223 
heterologous strains NADC20 and RFLP 1-7-4, an SVN assay was performed using serum 224 
samples collected at 49 dpv. When tested against the heterologous virus strain NADC20 (Fig. 225 
2A), both DS722- and VR2385-S3456-vaccinated pigs produced a higher level of NA titers, 226 
and the VR2385-S3456 group (mean value 5.5) was significantly higher than the DS722 227 
group (mean value 4.1). When tested against the heterologous virus strain RFLP 1-7-4 (Fig. 228 
2B), both vaccinated groups produced NAs, and the VR2385-S3456 group (mean value 2.4) 229 
was significantly higher than the DS722 group (mean value 1.7). Overall, the NA titers 230 
against the RFLP 1-7-4 strain were not as high as those against the NADC20 strain. 231 
Nevertheless, the results suggested that the chimeric virus VR2385-S3456 induced 232 
cross-neutralizing antibodies against heterologous PRRSV strains NADC20 and RFLP 1-7-4. 233 
3.4. Chimeric virus VR2385-S3456-vaccinated pigs had more average daily weight gain 234 
(ADWG) and less microscopic lung lesions after challenge 235 
  After challenge, three pigs in the PBS/NADC20 group, and two in the PBS/RFLP 1-7-4 236 
group developed mild respiratory symptoms (Table 2). Prior to challenge, there was no 237 
statistically significant difference in ADWG between any vaccinated groups and PBS control 238 
group (Fig. 3A). After challenge with heterologous strain NADC20, both DS722- and 239 
VR2385-S3456-vaccinated pigs had more ADWG than the PBS control group (Fig. 3B). 240 
After challenge with heterologous strain RFLP 1-7-4, the VR2385-S3456-vaccinated pigs 241 
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had more ADWG than DS722-vaccinated and PBS control pigs (Fig. 3B).  242 
  For microscopic lung lesions, the VR2385-S3456-vaccinated group had lower lesion 243 
scores than the DS722-vaccinated group when challenged with NADC20 (Fig. 3C). The 244 
VR2385-S3456-vaccinated group had numerically lower microscopic lung lesion scores, 245 
although not statistically significant, than the DS722-vaccinated group when challenged with 246 
RFLP 1-7-4 (Fig. 3D). The gross lung lesion scores were not statistically different between 247 
groups (data not shown). 248 
3.5. Chimeric virus VR2385-S3456-vaccinated pigs had reduced viral RNA loads in sera and 249 
lung tissues after challenge 250 
Viral RNA loads in serum and lung are routinely used as a parameter for measuring virus 251 
replication level for PRRSV studies [30, 37, 38]. Only one pig in the 252 
VR2385-S3456/NADC20 group had a low but detectable PRRSV viremia (1.6×103 copies/ml) 253 
at 49 dpv (Table 2) indicating that most pigs had cleared the residual vaccine virus at the 254 
time of challenge. When challenged with NADC20, both DS722- and 255 
VR2385-S3456-vaccinated groups had significantly reduced levels of serum viral RNA 256 
copies at 7, 14 dpc compared to the non-vaccinated group (Fig. 4A, B). Compared to the 257 
DS722-vaccinated group, the VR2385-S3456-vaccinated group had a numerically lower viral 258 
RNA copies, although the difference was not significant. 62.5% (5/8) pigs in the 259 
DS722-vaccinated group, and 85.7% (6/7) pigs in the VR2385-S3456-vaccinated group were 260 
negative for viral RNAs in sera at 14 dpc. Also, the viral RNA loads in the lung tissues of 261 
both DS722- and VR2385-S3456-vaccinated groups were significantly decreased when 262 
compared to the non-vaccinated control group (Fig. 4C). The VR2385-S3456-vaccinated pigs 263 
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showed numerically lower viral RNA loads, although not significantly different, in lung 264 
tissues than the DS722-vaccinated group.  265 
For pigs challenged with RFLP 1-7-4, both DS722- and VR2385-S3456-vaccinated groups 266 
had significantly decreased levels of viral RNA loads in sera (7, 14 dpc) and lung tissues (14 267 
dpc) compared to the non-vaccinated control group (Fig. 4D-4F). Similarly, the 268 
VR2385-S3456-vaccinated group had a numerically lower viral RNA copy number than that 269 
of DS722-vaccinated group, although the difference was not statistically significant. 62.5% 270 
(5/8) of pigs in the DS722-vaccinated and 71.4% (5/7) of VR2385-S3456-vaccinated groups 271 
were negative for viral RNA loads in lung tissues at 14 dpc. 272 
3.6. Chimeric virus VR2385-S3456 was genetically stable in vitro and in vivo 273 
  To investigate the genetic stability of the chimeric virus VR2385-S3456, the virus was 274 
serially passaged to P8 in MARC-145 cells. The ORFs3-6 sequences of the P8 virus showed 275 
a 99.9% nucleotide sequence identity to the P3 virus. The chimeric virus recovered from the 276 
serum samples of infected pigs at 14 dpv had 99.8% nucleotide sequence identity to that of 277 
the original virus. 278 
 279 
4. Discussion 280 
  The extensive genetic and antigenic diversity of field PRRSV strains worldwide makes the 281 
current commercial vaccines, which are all based on a single virus strain, less effective in 282 
protection against diverse field strains [9, 11, 39]. Enhancing cross-protection is critically 283 
important but a major challenge for the development of the next generation PRRSV vaccines 284 
[10, 13, 40, 41]. To overcome this challenge, one strategy is to expand the antigenic coverage 285 
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of PRRSV vaccines [12]. Molecular breeding through DNA shuffling has been shown to be a 286 
very promising approach to expand the antigenic coverage [15, 42, 43].  287 
  Previously, we successfully generated a chimeric virus FV-SPDS-VR2 containing only the 288 
ectodomains of the shuffled structural genes (ORFs3-6) in the genomic backbone of a 289 
commercial vaccine [32]. In this present study, we constructed a novel and improved 290 
chimeric virus VR2385-S3456. Compared to FV-SPDS-VR2, the novel chimeric virus 291 
VR2385-S3456 from this study has two key improvements: (1) It contains the full-length, not 292 
just the ectodomains, sequences of each shuffled structural genes; (2) The full-length 293 
sequences of the shuffled structural genes from multiple strains were cloned into the genomic 294 
backbone of PRRSV strain VR2385, which was originally used to screen those single 295 
gene-shuffled chimeras with significantly higher cross-neutralizing activities [29-31].  296 
  The vaccine efficacy of the novel chimera VR2385-S3456 was tested in a 297 
vaccination/challenge pig model. The results showed that the novel chimera VR2385-S3456 298 
conferred an enhanced cross-protection against heterologous virus strains NADC20 and 299 
RFLP 1-7-4. In the parental virus control group, we used the chimera DS722 virus which 300 
contains the shuffled GP5 gene. The DS722 has previously been shown to induce similar 301 
immune protection compared to the wild-type virulent VR2385 but is attenuated in pigs [30]. 302 
After vaccination, both DS722- and VR2385-S3456-vaccinated pigs had similar ADWG to 303 
the PBS control pigs, suggesting a good safety of both DS722 and VR2385-S3456. Although 304 
cell-mediated immunity is also important for protection against PRRSV, neutralizing 305 
antibodies is an important parameter to assess protection in pigs against PRRSV infection [32, 306 
37, 40]. At 49 dpv, VR2385-S3456-vaccinated pigs produced higher NA titers against 307 
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heterologous strains NADC20 and RFLP 1-7-4. Based on the ORF5 sequences, the RFLP 308 
1-7-4 strain used in this study as well as the strain MN184B both belong to genetic lineage 1 309 
[8]. Protection against lineage 1 strains is important, as the lineage 1 virus is currently highly 310 
prevalent [38, 41]. Unfortunately all the chimeric viruses from previously studies induced 311 
only very low NA titers (<1) against the lineage 1 MN184B strain [32]. In this present study, 312 
we found that most of VR2385-S3456-vaccinated pigs (11/14) and some of 313 
DS722-vaccinated pigs (6/16) elicited relatively higher NA titers (>2) against the lineage 1 314 
RFLP 1-7-4. It remains to be determined if the aforementioned two improvements of the 315 
novel chimera VR2385-S3456 are responsible for the observed higher NA titers against a 316 
lineage 1 virus strain. 317 
  When challenged with the heterologous strain NADC20, the VR2385-S3456-vaccinated 318 
pigs had an improved ADWG, lower microscopic lung lesion scores, reduced viral RNA 319 
loads in sera and lung tissues than the DS722-vaccinated or PBS control pigs. Importantly, 320 
most of VR2385-S3456-vaccinated pigs had cleared the viruses at necropsy. The data 321 
indicated that VR2385-S3456 conferred cross-protection against the heterologous strain 322 
NADC20.  323 
When challenged with a contemporary lineage 1 virus RFLP 1-7-4 which is currently 324 
circulating in North America, similar results were observed, suggesting a good protection 325 
against the heterologous strain RFLP 1-7-4. We noticed that the chimera DS722 also 326 
provided a partial protection against the two heterologous strains, indicating that the shuffled 327 
GP5 gene, which is the same for chimera DS722 and chimera VR2385-S3456, may have 328 
played a role in cross-protection as well. 329 
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In summary, in this study we successfully generated a novel chimeric virus VR2385-S3456 330 
which contains the full-length sequences of each shuffled structural genes of ORFs 3-6 in the 331 
genomic backbone of a PRRSV strain VR2385. The rescued chimeric virus had a reduced 332 
replication ability in vitro, induced relatively higher NA titers, and conferred an enhanced 333 
cross-protection in pigs against two heterologous virus strains. Therefore, the novel chimeric 334 
virus VR2385-S3456 is a good candidate for further development as a PRRSV vaccine.  335 
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Table 1. Experimental design for the cross-protective vaccine efficacy study in pigs 477 
Group No. of pigs Vaccination at 0 dpva 
with 
Challenge at 49 dpvb 
with 
No. of pigs at 
necropsy (14 dpc) 
1 8 PBS NADC20  8 
2 8 PBS RFLP 1-7-4 8 
3 8 DS722 NADC20 8 
4 8 DS722 RFLP 1-7-4  8 
5 8 VR2385-S3456 NADC20 7c 
6 8 VR2385-S3456 RFLP 1-7-4 7c 
a Dose: 1.0×104.0 TCID50/pig. Route: intramuscular injection (IM). 478 
b Dose: NADC20, 1.0×105.0 TCID50/pig; RFLP 1-7-4, 5.0×104.0 TCID50/pig. Route: 479 
intramuscular injection (IM). 480 
c One piglet died from an unrelated cause before challenge. 481 
dpv=days post-vaccination; dpc=days post-challenge 482 
 483 
484 
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Table 2. Seroconversion, serum viral RNA loads, and clinical signs of pigs 485 
Group No. of pigs 
seroconverted/totala 
No. of pigs  
serum viral RNA at 
49 dpv/totalb 
No. of pigs 
clinical sign 
(after 
challenge)/total 
7 14 21 28 35 42 49 dpv 
1 0/8 0/8 0/8 0/8 0/8 0/8 0/8 0/8 3/8 
2 0/8 0/8 0/8 0/8 0/8 0/8 0/8 0/8 2/8 
3 0/8 8/8 8/8 ND ND ND 8/8 0/8 0/8 
4 0/8 8/8 8/8 ND ND ND 8/8 0/8 0/8 
5 0/8 7/7 7/7 ND ND ND 7/7 1/7 0/7 
6 0/8 7/7 7/7 ND ND ND 7/7 0/7 0/7 
a Seroconversion was monitored using IDEXX HerdChek® X3 ELISA kit. ND, not done.  486 
b Serum viral RNA load was determined by RT-qPCR. 487 
 488 
489 
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Figure legends 490 
FIG. 1. Construction and virological characteristics of a novel chimeric virus 491 
VR2385-S3456. (A). Schematic diagrams of the genomic organization of the genomic 492 
backbone VR2385 virus and the novel chimeric virus VR2385-S3456. The genes derived 493 
from the backbone VR2385 virus are depicted with open rectangles. Each pattern in the genes 494 
of the shuffled ORFs3-6 represents a single shuffled gene derived from one of the single 495 
gene-shuffled chimeric viruses (GP3TS22, GP4TS14, DS722, MTS57) respectively, which 496 
are shown at the bottom. (B). Two days post-transfection of BHK-21 cells with the VR2385 497 
backbone as well as the novel chimeric virus clone, the P0 virus supernatants were harvested 498 
and used to inoculate fresh MARC-145 cells. Cells were fixed at 48 h post-inoculation, and 499 
immunostained by IFA with anti-PRRSV N monoclonal antibody (SDOW17). The parental 500 
virus VR2385 and the rescued novel chimeric virus VR2385-S3456 were passaged in 501 
MARC-145 cells to P3. (C). The P3 virus was used to infect fresh MARC-145 cells at an 502 
MOI of 0.1. The culture supernatants were collected at indicated time points. Infectious titers 503 
were determined and calculated using the Reed-Muench method. Three independent 504 
experiments were carried out for each virus. (D). Plaque morphology. The P3 viruses were 505 
used to infect MARC-145 cells, and then overlaid with medium containing 2% FBS and 1% 506 
low-melting-point agarose. Four days later, the cells were visualized by crystal violet 507 
staining.  508 
 509 
FIG. 2. Neutralizing antibody (NA) titers induced by the novel chimeric virus 510 
VR2385-S3456 in pigs against heterologous PRRSV strains NADC20 and RFLP 1-7-4. 511 
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At 49 dpv, the sera from vaccinated and control pigs were collected to determine the NA 512 
titers using MARC-145 cells by serum virus neutralization (SVN) assay. The NA titers were 513 
expressed as the highest dilution (2n) that showed a 90% or above reduction in the number of 514 
fluorescent foci compared to that of negative control serum. (A). NA against a heterologous 515 
strain NADC20. (B). NA against a contemporary heterologous strain RFLP 1-7-4. Each plot 516 
represents the mean titer of three separate tests, and the error bars indicate standard errors. P 517 
values were shown (** P<0.01, **** P<0.0001). 518 
 519 
FIG. 3. Average daily weight gain and microscopic lung lesions of vaccinated pigs. 520 
Average daily weight gain (ADWG) before (A) and after (B) virus challenge in vaccinated 521 
pigs. The pigs were weighed at the time of vaccination (0 dpv), challenge (49 dpv) and 522 
necropsy (14 dpc), respectively. For the evaluation of histological lung lesions, the lung 523 
tissues were fixed in formalin and scored for histological lesions by a board-certified 524 
veterinary pathologist (C, D). Each plot represents the value of one pig, and the error bars 525 
indicate standard errors. Significant difference is indicated with asterisks (* P<0.05). 526 
 527 
FIG. 4. Viral RNA loads in sera and lung tissues after challenge with heterologous virus 528 
strains NADC20 and RFLP 1-7-4.  PRRSV RNA copy numbers in sera at 7 dpc (A, D) 529 
and 14 dpc (B, E), and in lung tissues at 14 dpc (C, F) were determined by RT-qPCR. The 530 
detection limit is 3 log10 copies per ml (serum) or gram (lung tissue). Samples below the 531 
detection limit were considered as negative, and calculated as 2 log10 copies for statistical 532 
analysis. Each plot represents the mean viral RNA copy number of triplicate testing results of 533 
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one pig, and the error bars indicate standard errors. P values were shown (* P<0.05, ** 534 
P<0.01, *** P<0.001, **** P<0.0001). 535 
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